Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 26;11(11):3008.
doi: 10.3390/jcm11113008.

Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

Affiliations
Review

Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

Clara Bonanad et al. J Clin Med. .

Abstract

The treatment of acute coronary syndrome (ACS) in elderly patients continues to be a challenge because of the characteS.G.B.ristics of this population and the lack of data and specific recommendations. This review summarizes the current evidence about critical points of oral antithrombotic therapy in elderly patients. To this end, we discuss the peculiarities and differences reported referring to dual antiplatelet therapy (DAPT) in ACS management in elderly patients and what might be the best option considering these population characteristics. Furthermore, we analyze antithrombotic strategies in patients with atrial fibrillation (AF), with a particular focus on those cases that also present coronary artery disease (CAD). It is imperative to deepen our knowledge regarding the management of these challenging patients through real-world data and specifically designed geriatric studies to help resolve the questions remaining in their disease management.

Keywords: acute coronary syndrome; antiplatelet therapy; clopidogrel; elderly; prasugrel; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

D.V. reports scientific consulting with AstraZeneca, Bayer, Lilly, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS. C.B. reports scientific consulting with AstraZeneca, Bayer, Lilly, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS. JLF reports (a) honoraria for lectures from Eli Lilly Co., Daiichi Sankyo, Inc., AstraZeneca, Roche Diagnostics, Pfizer, Abbott, Ferrer, Boehringer Ingelheim, Bristol-Myers Squibb, and Rovi; (b) consulting fees from AstraZeneca, Eli Lilly Co., Ferrer, Boston Scientific, Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Bristol-Myers Squibb; (c) research grants from AstraZeneca. J.N. reports personal fees from AstraZeneca, Novartis, Boehringer-Ingelheim, Eli Lilly Co., Rovi, NovoNordisk, and Vifor Pharma. S.R.R. reports scientific consulting with AstraZeneca, Amgen, Bayer, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS.

Similar articles

Cited by

References

    1. Luca L.D., Servi S.D., Musumeci G., Bolognese L. Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes? Eur. Heart J. Cardiovasc. Pharmacother. 2018;4:12–14. doi: 10.1093/ehjcvp/pvx034. - DOI - PubMed
    1. Jiménez-Méndez C., Díez-Villanueva P., Alfonso F. Non-ST segment elevation myocardial infarction in the elderly. Rev. Cardiovasc. Med. 2021;22:779–786. doi: 10.31083/j.rcm2203084. - DOI - PubMed
    1. Tantry U.S., Navarese E.P., Myat A., Chaudhary R., Gurbel P.A. Combination oral antithrombotic therapy for the treatment of myocardial infarction: Recent developments. Expert Opin. Pharmacother. 2018;19:653–665. doi: 10.1080/14656566.2018.1457649. - DOI - PubMed
    1. Capranzano P., Angiolillo D.J. Tailoring P2Y12 Inhibiting Therapy in Elderly Patients with Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J. Am. Heart Assoc. 2019;8:e014000. doi: 10.1161/JAHA.119.014000. - DOI - PMC - PubMed
    1. Andreotti F., Rocca B., Husted S., Ajjan R.A., Berg J.T., Cattaneo M., Collet J.P., De Caterina R., Fox K.A., Halvorsen S., et al. Antithrombotic therapy in the elderly: Expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 2015;36:3238–3249. doi: 10.1093/eurheartj/ehv304. - DOI - PubMed